Amgen, Inc. vs MasTec Inc — how do they compare? Amgen, Inc. trades at $412.77 (market cap $224.14B), while MasTec Inc trades at $277.54 (market cap $21.90B). The key difference: Amgen, Inc. is far larger — about 10.2× MasTec Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while MasTec Inc pays none. Which is the better fit depends on your goals.
| AMGN | MTZ | |
|---|---|---|
Market Cap | $224.14B | $21.90B |
Sector | Health | Technology |
52-Week High | $417.20 | $437.51 |
52-Week Low | $271.18 | $172.51 |
Enterprise Value | $267.45B | $24.81B |
Dividend Yield | 2.43% | — |
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →